18 F-labeled Bisphosphonate as an Alternative Candidate to the Gold Standard[18F]sodium fluoride ([18F]NaF) for PET Bone Imaging
Bone metastases are a common source of malignancy in the skeleton and occur much more often than primary bone cancer. Several works were being performed to identify early markers for bone metastasis and novel drug targets to improve patients' quality of life. As some concerns exist with the [18...
| Published in: | Current Medical Imaging |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | English |
| Published: |
Bentham Science Publishers
2021
|
| Online Access: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122772883&doi=10.2174%2f1573405617666210216091202&partnerID=40&md5=bf9bec452a05d67facebcaf9b5d81ecf |
| Summary: | Bone metastases are a common source of malignancy in the skeleton and occur much more often than primary bone cancer. Several works were being performed to identify early markers for bone metastasis and novel drug targets to improve patients' quality of life. As some concerns exist with the [18F]sodiumfluoridein positron emission tomography (PET) bone imaging, there has been an increase in the number of targeted radiopharmaceutical markers for bone metastases imaging in its competitor,68Ga. Since18F properties are superior to those of68Ga, there is a distinct motivation for developing18F radiopharmaceuticals for bone metastases imaging. © 2021 Bentham Science Publishers. |
|---|---|
| ISSN: | 15734056 |
| DOI: | 10.2174/1573405617666210216091202 |